Despite the possible impact of the HER2, the significant suppression of Ki67 with irosustat provides proof of concept that inhibition of STS can affect tumour proliferation and based on the limited number of cases is at least comparable to tamoxifen. The gene discussed is ERBB2; the disease is neoplasm.